ClinicalTrials.gg
CompletedNCT02475733Updated Aug 9, 2018Results posted

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

A Phase 2 interventional study of Ceftazidime -avibactam and Meropenem in Complicated Intra-abdominal Infections, sponsored by Pfizer. Completed at 35 sites in 10 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-08-09.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
3 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.

Enrollment
8th of 14
83 · median 144
Started
2015
with 1 other
Phase 2
4 of 19
none open now
Registered
16th of 19
by date

Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 16th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 3 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Intraabdominal Infections by Pfizer as a file.
02

Study summary

This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal infections (cIAIs)

Read the detailed description

This is a multicentre, multinational, single blind, randomised and active controlled trial of intravenous ceftazidime avibactam in combination with metronidazole versus meropenem. Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before having the option to switch to an oral therapy. The decision to switch to oral therapy is entirely at the Investigator's discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food.Patients will be assessed for safety and efficacy throughout the study, and blood samples will be taken for pharmacokinetic (PK) assessment. The duration of each patient's participation in the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment (defined as the time point at which first dose of study treatment is administered) at which time there will be a late follow up (LFU) assessment visit. The LFU is to be performed 20 to 35 days after the last dose of any treatment.The assessments at the test of cure (TOC) visit should be performed in person 8 to 15 days after last dose of any study drug (IV or oral). The maximum duration of IV study drug or oral switch therapy is up to Day 15.

03

Conditions studied

  • Complicated Intra-abdominal Infections
04

Who can participate

Ages eligible
3 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be ≥3 calendar months to \<18 years of age. Patients aged ≥3 calendar months to \<1 year must have been born at term (defined as gestational age ≥37 weeks).
  2. Written from parent(s) or other legally acceptable representative(s), and informed assent from patient (if age appropriate according to local regulations)
  3. If female and has reached menarche, or has reached Tanner stage 3 development (even if not having reached menarche) (refer to Appendix E for further details on Tanner staging), the patient is authorised to participate in this clinical study if the following criteria are met:

At screening:

(i) Patient reports sexual abstinence for the prior 3 months or reports use of at least 1 of the acceptable methods of , including an intrauterine device (with copper banded coil), levonorgestrel intrauterine system (eg, Mirena®), or regular medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment with study drug; and (ii) Patient is advised to avoid conception from the time of screening until 7 days after receipt of study drug and agrees not to attempt pregnancy from the time of screening until 7 days after end of treatment with study drug; and (iii) Patient is provided guidelines regarding continuation of abstinence, initiation of abstinence, or about allowed contraception; and (iv) Patient has a negative serum β-human chorionic gonadotropin (β-hCG) test just prior to study entry. Since serum tests may miss an early pregnancy, relevant menstrual history and sexual history, including methods of contraception, should be considered. Note: if the result of the serum β-hCG test cannot be obtained prior to dosing of product, a patient may be enrolled on the basis of a negative urine pregnancy test, though a serum β-hCG test result must still be obtained.

  1. Must, based on the judgment of the Investigator, require hospitalisation initially and antibacterial therapy for 7 to 15 days in addition to surgical intervention for the treatment of the current cIAI 5. Require surgical intervention (eg, laparotomy, laparoscopic surgery or percutaneous drainage) to manage the cIAI 6. Must have clinical evidence of cIAI as follows: (i) Pre-operative enrolment inclusion:
  1. Requires surgical intervention that is expected to be completed within 24 hours of enrolment Laparotomy, laparoscopy, or percutaneous drainage
  2. Evidence of a systemic inflammatory response (at least 1): Fever (defined as oral temperature >38.5°C, or equivalent to method used) or hypothermia (with a core body or rectal temperature \<35°C, or equivalent to method used) Elevated white blood cells (WBC) (>15000 cells/mm3) C-reactive protein (CRP) levels (>10 mg/L)
  3. Physical Findings consistent with intra-abdominal infection, such as:

    Abdominal pain and/or tenderness Localised or diffuse abdominal wall rigidity Abdominal mass

  4. Intention to send specimens from the surgical intervention for culture
  5. (Optional) Supportive radiologic findings of intra-abdominal infection, such as perforated intraperitoneal abscess detected on: Computed tomography (CT) scan or Magnetic resonance imaging (MRI) or Ultrasound (ii) Intra-operative/postoperative enrolment inclusion(in cases of postoperative enrolment, must be within 24 hours after the time of incision)::

Visual confirmation of intra-abdominal infection associated with peritonitis at laparotomy, laparoscopy or percutaneous drainage (to be confirmed pending feasibility); must have 1 of these diagnoses:

  1. Appendiceal perforation or peri-appendiceal abscess
  2. Cholecystitis with gangrenous rupture or perforation or progression of the infection beyond the gallbladder wall
  3. Acute gastric or duodenal perforations, only if operated on >24 hours after singular perforation occurs
  4. Traumatic perforation of the intestines, only if operated on >12 hours after perforation occurs
  5. Secondary peritonitis (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites)

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous enrolment or randomisation in the present study
  3. Participation in another clinical study with an product (IP) during the last 30 days before the first dose of IV study drug or have previously participated in the current study or in another study of CAZ-AVI (in which an active agent was received)
  4. History of reactions to carbapenems, cephalosporins, penicillin, other β lactam antibiotics metronidazole or to nitroimidazole derivatives
  5. Concurrent infection, that may interfere with the evaluation of response to the study antibiotics at the time of randomisation
  6. Patient needs effective concomitant systemic antibacterials (oral, IV, or intramuscular) in addition to those designated in the 2 study groups (CAZ-AVI plus metronidazole group or meropenem group) (see Section 7.8)
  7. Receipt of non-study systemic antibacterial drug therapy for cIAI for a continuous duration of more than 24 hours during the 72 hours preceding the first dose of IV drug, except in proven resistant organisms and/or worsening of the clinical condition for more than 24 hours. More than 2 consecutive doses are not permitted if the individual doses are expected to give >12 hours' cover (ie, giving a total cover of >24 hours.) For patients enrolled after a surgical procedure, only 1 dose of non study antibiotics is permitted postoperatively
  8. Patient is considered unlikely to survive the 6 to 8 week study period
  9. Patient is unlikely to respond to 7 to 15 days of treatment with antibiotics
  10. Patient is receiving haemodialysis or peritoneal dialysis
  11. Diagnosis of abdominal wall abscess confined to musculature of the abdominal wall or ischaemic bowel disease without perforation, traumatic bowel perforation requiring surgery within 12 hours of perforation, or perforation of gastroduodenal ulcers requiring surgery within 24 hours of perforation (these are considered situations of peritoneal soiling before the infection has become established)
  12. Simple (uncomplicated), non-perforated appendicitis or gangrenous appendicitis without rupture into the peritoneal cavity identified during a surgical procedure OR presence of primary peritonitis (ie, spontaneous bacterial peritonitis) or peritonitis associated with cirrhosis or chronic ascites
  13. At the time of randomisation, patient is known to have a cIAI caused by pathogens resistant to the study antimicrobials planned to be used in the study
  14. Presence of any of the following laboratory abnormalities:

    1. Haematocrit \<25% or \<8 g/dL (\<80g/L , \<4.9 mmol/L)
    2. Serum (ALT) or aspartate aminotransferase (AST) >3×the age-specific (ULN), or total >2×ULN (except known Gilbert's disease) For a) to b): unless if these values are acute and directly related to the infectious process being treated.
  15. \<30 mL/min /1.73 m2 calculated using the child's measured height (length) and serum creatinine within the updated "bedside" Schwartz formula (Schwartz et al, 2009):

    CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)

  16. History of seizures, excluding well-documented febrile seizure of childhood
  17. Any situation or condition that would make the patient, in the opinion of the Investigator, unsuitable for the study (eg, would place a patient at risk or compromise the quality of the data) or may interfere with optimal participation in the study
  18. If female, currently pregnant or breast feeding
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    CAZ-AVI and metronidazole

    CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion

    Drug: Ceftazidime -avibactam · Drug: Metronidazole

  • Active comparator
    Meropenem

    administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.

    Drug: Meropenem

Interventions

  • DrugCeftazidime -avibactam

    Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment

  • Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment

  • Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment \[IV or oral\]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.

    Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)

  2. Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)

    Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure.

    Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)

  3. Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit

    EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)

  4. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit

    EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)

  5. Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit

    EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)

  6. Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit

    EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)

  7. Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit

    EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)

  8. Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit

    Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: EOIV visit (anytime from Day 4 up to 16)

  9. Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

    Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: \<0.7\*lower limit of normal range \[LLN\] and \>30 percent decrease from baseline \[DFB\]; alanine aminotransferase \[ALT\]: \>3\*upper limit of normal range \[ULN\] and \>300 percent IFB; alanine aminotransferase \[AST\]: \>3\*ULN and \>300 percent IFB) and hematology (platelets: \>2\*ULN and \>100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)

  10. Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)

    ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF \>450 millisecond (ms); maximum QTcF \>480 ms; and maximum QTcF \>500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: Baseline until the EOIV visit (anytime from Day 4 to 16)

  11. Percentage of Participants With Creatinine Clearance (CrCl) at Day 7

    CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2.

    Time frame: Day 7

  12. Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit

    CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: EOIV visit (anytime from Day 4 up to 16)

  13. Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit

    CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

    Time frame: TOC visit (up to a maximum study duration of 50 days)

  14. Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit

    CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: LFU visit (up to a maximum study duration of 50 days)

Secondary outcomes

  1. Plasma Concentrations of Ceftazidime and Avibactam

    Time frame: 15, 30-90, 300-360 minutes post-dose on Day 3

  2. Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population

    Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells \[WBCs\], elevated c-reactive protein) from baseline and no worsening symptom/sign.

    Time frame: End of 72 hours study drug treatment on Day 1

  3. Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population

    Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

    Time frame: EOIV visit (anytime from Day 4 up to 16)

  4. Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population

    Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy).

    Time frame: EOT visit (up to Day 17)

  5. Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population

    Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

    Time frame: TOC visit (up to a maximum study duration of 50 days)

  6. Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population

    Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

    Time frame: End of 72 hours study drug treatment on Day 1, EOIV (anytime from Day 4 up to 16), EOT visit (up to Day 17) and TOC visit (up to a maximum study duration of 50 days)

  7. Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population

    Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

  8. Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population

    Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)

  9. Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population

    A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: LFU visit (up to a maximum study duration of 50 days)

  10. Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population

    A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

    Time frame: LFU visit (up to a maximum study duration of 50 days)

  11. Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population

    Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported.

    Time frame: Baseline up to 50 days

  12. Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population

    Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported.

    Time frame: TOC visit (up to a maximum study duration of 50 days)

07

Results

Posted Aug 9, 2018

Participant flow

Participant flow — Overall Study
MilestoneCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Started6122
Completed5922
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Physician decision10

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment \[IV or oral\]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.

Time frame:
Baseline until the LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
AEs52.559.1
SAEs8.24.5
PrimaryPercentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)

Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure.

Time frame:
Baseline until the LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
AE in the ST of Diarrhea1.60
AEoSI in the ST of Hypersensitivity/Anaphylaxis4.913.6
AE in the ST of Liver Disorder00
AE in the ST of Renal Disorder00
AEs with PTs in the Nervous System Disorder SOC1.64.5
AE of seizure00
PrimaryChange From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline, EOIV visit (anytime from Day 4 up to 16)
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit
beats per minuteCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Baseline102.1 ± 17.07103.0 ± 23.31
Change at EOIV-15.2 ± 20.45-15.4 ± 21.74
PrimaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline, EOIV visit (anytime from Day 4 up to 16)
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit
millimeter of mercury (mmHg)Ceftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
SBP: Baseline109.7 ± 13.90111.6 ± 13.06
SBP: Change at EOIV-4.0 ± 12.32-6.0 ± 13.66
DBP: Baseline63.5 ± 10.3663.1 ± 13.51
DBP: Change at EOIV1.3 ± 11.99-2.8 ± 14.14
PrimaryChange From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline, EOIV visit (anytime from Day 4 up to 16)
Reported as:
Mean · breaths per minute
Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit
breaths per minuteCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Baseline22.4 ± 5.0222.9 ± 5.79
Change at EOIV-1.3 ± 4.57-1.3 ± 4.44
PrimaryChange From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline, EOIV visit (anytime from Day 4 up to 16)
Reported as:
Mean · kilograms
Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit
kilogramsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Baseline40.58 ± 16.28638.35 ± 16.685
Change at EOIV-0.38 ± 1.442-1.06 ± 1.490
PrimaryChange From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit

EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline, EOIV visit (anytime from Day 4 up to 16)
Reported as:
Mean · degree Celsius
Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit
degree CelsiusCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Baseline37.35 ± 1.03537.16 ± 0.914
Change at EOIV-0.78 ± 0.987-0.60 ± 0.780
PrimaryPercentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit

Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
EOIV visit (anytime from Day 4 up to 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Abdomen6.618.2
Cardiovascular System00
General Appearance1.60
Head and Neck00
Lymph Nodes00
Musculoskeletal System00
Neurological System00
Respiratory System3.30
Skin1.60
Thyroid00
PrimaryPercentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: \<0.7\*lower limit of normal range \[LLN\] and \>30 percent decrease from baseline \[DFB\]; alanine aminotransferase \[ALT\]: \>3\*upper limit of normal range \[ULN\] and \>300 percent IFB; alanine aminotransferase \[AST\]: \>3\*ULN and \>300 percent IFB) and hematology (platelets: \>2\*ULN and \>100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
Baseline until the LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Chemistry: Calcium1.90
Chemistry: ALT1.70
Chemistry: AST1.80
Hematology: Platelets3.30
PrimaryPercentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)

ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF \>450 millisecond (ms); maximum QTcF \>480 ms; and maximum QTcF \>500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
Baseline until the EOIV visit (anytime from Day 4 to 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Maximum QTcF Interval : >450 ms1.64.5
Maximum QTcF Interval : >480 ms1.64.5
Maximum QTcF Interval : >500 ms04.5
PrimaryPercentage of Participants With Creatinine Clearance (CrCl) at Day 7

CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2.

Time frame:
Day 7
Reported as:
Number · percentage of participants
Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
CrCl: <30mL/min/1.73 m^200
CrCl: >=30 to <50mL/min/1.73 m^200
CrCl: >=50 to <80mL/min/1.73 m^200
CrCl: >=80mL/min/1.73 m^250.859.1
PrimaryPercentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
EOIV visit (anytime from Day 4 up to 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
CrCl: <30mL/min/1.73 m^200
CrCl: >=30 to <50mL/min/1.73 m^200
CrCl: >=50 to <80mL/min/1.73 m^200
CrCl: >=80mL/min/1.73 m^282.081.8
PrimaryPercentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

Time frame:
TOC visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
CrCl: <30mL/min/1.73 m^200
CrCl: >=30 to <50mL/min/1.73 m^200
CrCl: >=50 to <80mL/min/1.73 m^23.30
CrCl: >=80mL/min/1.73 m^242.659.1
PrimaryPercentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit

CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
CrCl: <30mL/min/1.73 m^200
CrCl: >=30 to <50mL/min/1.73 m^200
CrCl: >=50 to <80mL/min/1.73 m^21.60
CrCl: >=80mL/min/1.73 m^26.69.1
SecondaryPlasma Concentrations of Ceftazidime and Avibactam
Time frame:
15, 30-90, 300-360 minutes post-dose on Day 3
Reported as:
Geometric mean · nanogram per milliliter
Plasma Concentrations of Ceftazidime and Avibactam
nanogram per milliliterCeftazidime- Avibactam (CAZ-AVI) Plus Metronidazole
Ceftazidime: 15 minute post-dose on Day 363565.5 ± 236761.80
Ceftazidime: 30-90 minute post-dose on Day 338048.0 ± 19810.95
Ceftazidime:300-360minute post-dose on Day 34603.0 ± 10308.96
Avibactam: 15 minute post-dose on Day 312186.2 ± 55720.44
Avibactam: 30-90 minute post-dose on Day 36548.6 ± 4437.55
Avibactam: 300-360 minute post-dose on Day 3821.5 ± 1968.21
SecondaryPercentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population

Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells \[WBCs\], elevated c-reactive protein) from baseline and no worsening symptom/sign.

Time frame:
End of 72 hours study drug treatment on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population93.4 (85.2 to 97.7)90.9 (73.9 to 98.1)
SecondaryPercentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.

Time frame:
EOIV visit (anytime from Day 4 up to 16)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population96.7 (89.9 to 99.3)100 (89.3 to 100)
SecondaryPercentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy).

Time frame:
EOT visit (up to Day 17)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population91.8 (83.0 to 96.8)100 (89.3 to 100)
SecondaryPercentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

Time frame:
TOC visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population91.8 (83.0 to 96.8)95.5 (80.7 to 99.5)
SecondaryPercentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population

Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).

Time frame:
End of 72 hours study drug treatment on Day 1, EOIV (anytime from Day 4 up to 16), EOT visit (up to Day 17) and TOC visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
End 72 hours study medication98.0 (90.9 to 99.8)95.0 (78.9 to 99.5)
EOIV98.1 (91.7 to 99.8)100 (88.3 to 100)
EOT94.2 (85.4 to 98.3)100 (88.3 to 100)
TOC92.9 (83.9 to 97.5)95.0 (78.9 to 99.5)
SecondaryPercentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
EOIV96.0100
EOT90.0100
TOC90.094.7
LFU90.094.7
SecondaryPercentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population

Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
EOIV97.5100
EOT91.7100
TOC90.093.3
LFU89.292.9
SecondaryPercentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population

A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population00
SecondaryPercentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population

A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).

Time frame:
LFU visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population00
SecondaryPercentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population

Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported.

Time frame:
Baseline up to 50 days
Reported as:
Number · percentage of participants
Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population00
SecondaryPercentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population

Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported.

Time frame:
TOC visit (up to a maximum study duration of 50 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population
percentage of participantsCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population00

Adverse events

Collected over Baseline until the LFU visit (up to a maximum study duration of 50 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole0/61 (0%)5/61 (8.2%)14/61 (23%)
Meropenem0/22 (0%)1/22 (4.5%)6/22 (27.3%)
Most frequent serious events
Most frequent serious events
EventCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
IleusGastrointestinal disorders1/611/22
Intestinal obstructionGastrointestinal disorders1/610/22
Large intestine perforationGastrointestinal disorders1/610/22
Postoperative ileusInjury, poisoning and procedural complications1/610/22
Renal colicRenal and urinary disorders1/610/22
Urethral meatus stenosisRenal and urinary disorders1/610/22
Most frequent other events
Most frequent other events
EventCeftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenem
VomitingGastrointestinal disorders9/612/22
Abdominal painGastrointestinal disorders0/612/22
CoughRespiratory, thoracic and mediastinal disorders1/612/22
Infusion site phlebitisGeneral disorders4/610/22

Baseline characteristics

Intent-to-treat (ITT) analysis set included all participants who had been assigned a randomized treatment.

Age, Continuous
Age, Continuous(years)Ceftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenemTotal
Mean10.4 ± 3.649.7 ± 3.9710.2 ± 3.71
Sex: Female, Male
Sex: Female, Male(Participants)Ceftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenemTotal
Female171330
Male44953
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ceftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenemTotal
Hispanic or Latino12113
Not Hispanic or Latino492170
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ceftazidime- Avibactam (CAZ-AVI) Plus MetronidazoleMeropenemTotal
American Indian or Alaska Native101
Asian7411
Native Hawaiian or Other Pacific Islander000
Black or African American000
White531669
More than one race000
Unknown or Not Reported022
08

Study locations

35 sites
  • CHOC Children's
    Orange, California 92868, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • ProMedica Toledo Children's Hospital
    Toledo, Ohio 43606, United States
  • The Children's Hospital at Saint Francis
    Tulsa, Oklahoma 74136, United States
  • Oblastni Nemocnice Kolin, a.s., Nemocnice Stredoceskeho Kraje, Detske oddeleni
    Kolin III, 280 00, Czechia
  • Lekarna Oblastni Nemocnice Kolin, a.s.
    Kolin III, 280 02, Czechia
  • Krajska zdravotni, a.s. - Nemocnice Most, o.z., Detske a dorostove oddeleni
    Most, 434 64, Czechia
  • Lekarna Nemocnice Most, o.z.
    Most, 434 64, Czechia
  • Fakultni Nemocnice Ostrava - Klinika Detskeho Lekarstvi
    Ostrava - Poruba, 708 52, Czechia
  • Lekarna Fakultni Nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Lekarna Thomayerovy Nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • Thomayerova Nemocnice, Klinika detske chirurgie a traumatologie 3.LF UK a TN
    Praha 4 - Krc, 140 59, Czechia
  • Lekarna Nemocnice Strakonice
    Strakonice, 386 29, Czechia
  • Nemocnice Strakonice, a.s. - Detske oddeleni
    Strakonice, 386 29, Czechia
  • General Children's Hospital of Athens "P. & A.Kyriakou"
    Athens, Attica 11527, Greece
  • General Hospital of Thessaloniki "Hippokratio"
    Thessaloniki, Macedonia 54642, Greece
  • Semmelweis Egyetem, II. sz. Gyermekgyogyaszati Klinika
    Budapest, 1094, Hungary
  • Kanizsai Dorottya Korhaz, Csecsemo es Gyermekgyogyaszati Osztaly
    Nagykanizsa, 8800, Hungary
  • Pecsi Tudomanyegyetem, AOK, Klinikai Kozpont, Gyermekgyogyaszati Klinika
    Pecs, 7623, Hungary
  • Szegedi Tudomanyegyetem, Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Tolna Megyei Balassa Janos Korhaz, Gyermekgyogyaszati Osztaly
    Szekszard, 7100, Hungary
  • Uniwersytecki Szpital Dzieciecy w Lublinie
    Lublin, 20-093, Poland
  • Spitalul Clinic de Urgenta pentru Copii "Sf. Maria" Iasi, Sectia Chirurgie Pediatrica II
    Iasi, 700309, Romania
  • State Budgetary Educational Institution of Higher Professional Education
    Smolensk, Smolensk Region 214019, Russian Federation
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital de Sant Joan de Deu
    Esplugues de LLobregat, Barcelona 08950, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario y Politecnico la Fe
    Valencia, 46026, Spain
  • Kaohsiung Veterans General Hospital
    Kaohsiung, 81362, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 40705, Taiwan
  • Department of Pediatrics, Mackay Memorial Hospital
    Taipei, 10449, Taiwan
  • Cukurova Universitesi Tip Fakultesi Balcali Hastanesi
    Adana, 01330, Turkey
  • Eskisehir Osmangazi Universitesi Saglik Uygulama ve Arastirma Hastanesi
    Eskisehir, 26040, Turkey
  • Celal Bayar Universitesi Hafsa Sultan Hastanesi
    Manisa, 45030, Turkey
09

References and documents

Publications

  • Franzese RC, McFadyen L, Watson KJ, Riccobene T, Carrothers TJ, Vourvahis M, Chan PLS, Raber S, Bradley JS, Lovern M. Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. Clin Pharmacol Ther. 2022 Mar;111(3):635-645. doi: 10.1002/cpt.2460. Epub 2021 Nov 22. Erratum In: Clin Pharmacol Ther. 2024 Feb;115(2):373. doi: 10.1002/cpt.3143. PubMed 34687548 ↗
  • Bradley JS, Broadhurst H, Cheng K, Mendez M, Newell P, Prchlik M, Stone GG, Talley AK, Tawadrous M, Wajsbrot D, Yates K, Zuzova A, Gardner A. Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children >/=3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. Pediatr Infect Dis J. 2019 Aug;38(8):816-824. doi: 10.1097/INF.0000000000002392. PubMed 31306396 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Jun 2017, 22 months.

Results were first posted in Aug 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2015
First posted
Jun 19, 2015
StartActual
Aug 1, 2015
Primary completionActual
Jun 1, 2017
CompletionActual
Jun 1, 2017
Results first posted
Aug 9, 2018
Last update
Aug 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02475733
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 19, 2015
Start date
Aug 1, 2015
Primary completion
Jun 1, 2017
Completion
Jun 1, 2017
Results posted
Aug 9, 2018
Last update
Aug 9, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion